Could cost-saving Crohn's theranostic dent anti-TNF sales for Abbvie, Merck?
This article was originally published in Scrip
Executive Summary
Theradiag's Lisa-Tracker test for monitoring how well Crohn's disease patients are responding to tumor necrosis factor inhibitors, an expensive class of biologics, has shown it could potentially cut hospital spending on these drugs by up to 25% in France alone. While this spells good news for budget-conscious healthcare payers, it may not be as warmly received by the likes of Merck and Abbvie, whose respective anti-TNF products – Remicade (infliximab) and Humira (adalimumab) – are significant cash cows generating billions of dollars in revenue.